| Literature DB >> 26084281 |
Anette Larsson1,2, Annie Palstam3,4, Monika Löfgren5, Malin Ernberg6, Jan Bjersing7, Indre Bileviciute-Ljungar8, Björn Gerdle9,10, Eva Kosek11, Kaisa Mannerkorpi12,13,14.
Abstract
INTRODUCTION: Fibromyalgia (FM) is characterized by persistent widespread pain, increased pain sensitivity and tenderness. Muscle strength in women with FM is reduced compared to healthy women. The aim of this study was to examine the effects of a progressive resistance exercise program on muscle strength, health status, and current pain intensity in women with FM.Entities:
Mesh:
Year: 2015 PMID: 26084281 PMCID: PMC4489359 DOI: 10.1186/s13075-015-0679-1
Source DB: PubMed Journal: Arthritis Res Ther ISSN: 1478-6354 Impact factor: 5.156
Fig. 1Consolidated Standards of Reporting Trials (CONSORT) flow diagram of the progress of the two groups of the randomized trial. FM fibromyalgia
Characteristics of the study population
| Resistance exercise (experimental) | Relaxation therapy (control) | ||
|---|---|---|---|
| (n = 67) | (n = 63) | ||
| Mean (SD) | Mean (SD) | ||
| Characteristics | Median (min; max) | Median (min; max) | p value |
| Age, years | 50.81 (9.05) | 52.10 (9.78) | 0.27 |
| 51 (25; 64) | 55 (22; 64) | ||
| Symptom duration, years | 11.06 (8.53) | 9.44 (7.33) | 0.38 |
| 9 (0; 35) | 8 (0; 30) | ||
| Tender points, number | 15.76 (1.92) | 15.49 (2.00) | 0.48 |
| 16 (11; 18) | 16 (11; 18) | ||
| Body mass index | 27.39 (5.29) | 28.66 (5.32) | 0.06 |
| 26 (20; 41) | 27 (18; 43) | ||
| LTPAI, h | 5.62 (4.80) | 5.79 (6.25) | 0.52 |
| 4 (0; 28) | 4 (1; 38) | ||
| Number (%) | Number (%) | ||
| Pharmacologigal treatment | |||
| NSAID paracetamol | |||
| Yes | 53 (79 %) | 44 (70 %) | 0.22 |
| Opioids for mild to moderate pain | |||
| Yes | 13 (19 %) | 12 (19 %) | 1.00 |
| Antidepressants | |||
| Yes | 32 (48 %) | 24 (38 %) | 0.22 |
| Anticonvulsives | |||
| Yes | 4 (6 %) | 2 (3 %) | 0.68 |
| Sedatives | |||
| Yes | 11 (16 %) | 12 (19 %) | 0.82 |
| Education | |||
| ≤9 years | 8 (12 %) | 15 (24 %) | |
| 10–12 years | 34 (51 %) | 22 (35 %) | |
| >12 years | 25 (37 %) | 26 (41 %) | 0.88 |
| Living with an adult | |||
| Yes | 45 (67 %) | 40 (64 %) | 0.71 |
| Born in Sweden | 60 (90 %) | 56 (89 %) | 0.56 |
| Work status | |||
| 0 % | 29 (43 %) | 26 (41 %) | |
| 20–49 % | 2 (3 %) | 4 (6 %) | |
| 50 % | 13 (19 %) | 11 (18 %) | |
| 51–79 % | 8 (12 %) | 8 (13 %) | |
| 100 % | 15 (22 %) | 14 (22 %) | 0.71 |
| Sick leave/disability pension | |||
| 25 % | 9 (13 %) | 5 (8 %) | |
| 50 % | 16 (24 %) | 9 (14 %) | |
| 75 % | 2 (3 %) | 3 (5 %) | |
| 100 % | 21 (31 %) | 22 (35 %) | 0.86 |
Missing values, LTPAI: n = 1. NSAID non-steroidal anti-inflammatory drugs, LTPAI leisure time physical activity instrument
Comparison of baseline values for participants in the resistance exercise group who reached exercise loads of 80 % and participants in the resistance exercise group who reached exercise loads up to 60 %
| Resistance exercise (experimental) | |||
|---|---|---|---|
| Baseline values of participants reaching loads of 80 % | Baseline values of participants reaching loads ≤60 % | Comparison of baseline values between groups | |
| (n = 42) | (n = 25) | ||
| Measures | Mean (SD) | Mean (SD) |
|
| Median (min; max) | Median (min; max) | ||
| Age, years | 50.26 (9.65) | 51.7 (8.1) | 0.68 |
| 51 (25; 64) | 52 (33; 63) | ||
| Symptom duration, years | 11.44 (8.31) | 10.4 (9.0) | 0.47 |
| 10 (0; 35) | 8 (0; 30) | ||
| Tender point count, number | 15.57 (1.92) | 16.08 (1.91) | 0.30 |
| 16 (11; 18) | 17 (12; 18) | ||
| Body mass index | 26.75 (4.2) | 28.5 (6.7) | 0.48 |
| 26 (21; 36) | 27 (20; 41) | ||
| LTPAI, h | 4.87 (3.87) | 6.9 (5.9) | 0.17 |
| 4 (0;18) | 6 (1;28) | ||
| Primary outcome | |||
| Isometric knee-extension force, N | 347.3 (106.2) | 301.2 (110.7) | 0.11 |
| 344 (114;643) | 305 (111;585) | ||
| Secondary outcomes | |||
| FIQ total score (0-100) | 57.3 (12.7) | 65.9 (15.8) |
|
| 55.2 (31; 81) | 64 (40; 95) | ||
| Current pain intensity, visual analog scale | 49.5 (22.1) | 48.8 (27.19) | 0.68 |
| 54 (12; 89) | 50 (5;100) | ||
| 6MWT, m | 573.7 (70.3) | 527.7 (75.5) |
|
| 570 (376; 766) | 548 (360; 655) | ||
| Isometric elbow-flexion force, kg | 13.1 (5.3) | 12.9 (5.7) | 0.76 |
| 13 (2; 26) | 13 (3; 32) | ||
| Isometric hand-grip force, N | 168.4 (70.4) | 150.7 (65.6) | 0.30 |
| 162 (34; 319) | 169 (62; 315) | ||
| SF36 PCS, 0–100 | 31.7 (7.5) | 30.3 (8.8) | 0.32 |
| 31 (12; 49) | 30 (18; 49) | ||
| SF36 MCS, 0–100 | 39.8 (11.9) | 34.0 (12.1) | 0.10 |
| 41 (10; 59) | 35 (13; 61) | ||
| PDI, 0–70 | 34.3 (11.6) | 36.9 (13.4) | 0.40 |
| 34 (12; 69) | 39 (8; 62) | ||
| CPAQ total, 0–120 | 66.0 (14.5) | 59.5 (18.0) | 0.13 |
| 64 (35; 99) | 59 (19; 106) | ||
| FABQphysical, 0–24 | 9.0 (5.9) | 12.6 (7.1) | 0.23 |
| 9 (0; 23) | 13 (2; 24) | ||
| FABQwork, 0–42 | 16.1 (12.3) | 20.0 (13.9) | 0.37 |
| 14 (0; 42) | 21 (0; 39) | ||
6MWT 6 minute walk test, SF36 PCS Short Form 36 physical component scale, SF36 MCS Short Form 36 mental component scale, CPAQ chronic pain acceptance questionnaire, PDI pain disability index, FABQ fear avoidance beliefs questionnaire
Between-group analysis and within-group analysis of the primary and secondary outcomes
| Measures | Resistance exercise (experimental) | Relaxation therapy (control) | Between-group analysis of change | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline | Post test | Post-test- baseline | Within-group analysis | Baseline | Post test | Post-test- baseline | Within-group analysis | ||
| (n = 67) | (n = 56) | (n = 56) | (n = 63) | (n = 49) | (n = 49) | ||||
| Mean (SD) | Mean (SD) | Δ (SD) |
| Mean (SD) | Mean (SD) | Δ (SD) |
|
| |
| Median (min; max) | Median (min; max) | Δ (min; max) | Median (min; max) | Median (min; max) | Δ (min; max) | ||||
| Primary outcome | |||||||||
| Isometric knee-extension force, N | 330.1 (109.4) | 356.2 (118.9) | 30.4 (71.9) |
| 298.8 (107.8) | 276.4 (112.9) | −8.8 (70.0) | 0.644 |
|
| 326 (111; 643) | 342 (105; 663) | 31 (−157; 178) | 287 (51; 534) | 278 (41; 595) | −10 (−222; 132) | ||||
|
| |||||||||
| FIQ total, 0–100 | 60.5 (14.4) | 54.4 (18.2) | −5.7 (15.0) |
| 61.1 (17.3) | 59.3 (16.0) | 0.1 (12.9) | 0.71 |
|
| 59 (31; 95) | 55 (11; 88) | −3 (−51; 20) | 61 (17; 88) | 61 (21; 86) | 1 (−34; 25) | ||||
| Current pain intensity, VAS | 49.3 (23.9) | 38.6 (25.2) | −11.5 (25.1) |
| 52.4 (18.3) | 53.4 (20.0) | −1.5 (16.5) | 0.63 |
|
| 50 (5; 100) | 31 (0; 95) | −13 (−83; 48) | 51 (10; 88) | 56 (10; 86) | −2 (−51; 30) | ||||
| 6MWT, m | 556.6 (75.1) | 579.7 (73.7) | 18.4 (65.1) |
| 540.7 (64.5) | 533.9 (73.1) | −5.6 (43.5) | 0.51 |
|
| 566 (360; 766) | 582 (340; 762) | 24 (−290; 196) | 530 (362; 660) | 537 (366; 656) | 1 (−125; 101) | ||||
| Isometric elbow flexion force, kg | 13.0 (5.4) | 14.8 (5.6) | 2.4 (3.3) |
| 10.9 (5.2) | 11.7 (5.6) | 1.2 (3.3) |
|
|
| 13 (2; 32) | 15 (2; 27) | 2 (−5; 12) | 10 (2; 24) | 12 (3; 27) | 1 (−7; 13) | ||||
| Hand-grip force, N | 161.8 (68.7) | 181.1 (61.5) | 20.1 (36.1) |
| 139.4 (61.7) | 147.2 (66.7) | 14.0 (37.9) |
| 0.49 |
| 164 (34; 319) | 185 (38; 327) | 14 (−32; 158) | 134 (40; 311) | 146 (39; 327) | 9 (−101; 98) | ||||
| SF36 PCS, 0–100 | 31.2 (7.9) | 34.5 (9.1) | 3.3 (7.2) |
| 29.9 (8.1) | 30.7 (8.3) | 0.8 (5.7) | 0.28 | 0.11 |
| 31 (12; 50) | 35 (14; 54) | 3 (−13; 18) | 30 (10; 50) | 30 (17; 47) | 1 (−13; 13) | ||||
| SF36 MCS, 0–100 | 37.7 (12.2) | 42.0 (12.6) | 3.3 (10.3) |
| 39.6 (12.1) | 38.8 (12.9) | −0.4 (9.5) | 0.86 | 0.054 |
| 37 (10; 61) | 44 (12; 62) | 3 (−23; 35) | 42 (16; 59) | 41 (13; 61) | 0 (−22; 23) | ||||
| PDI, 0–70 | 35.3 (12.2) | 32.2 (13.1) | −3.8 (10.6) |
| 35.0 (12.5) | 35.7 (12.4) | 1.4 (9.0) | 0.27 |
|
| 36 (8; 69) | 34 (7; 67) | −5 (−29; 23) | 34 (7; 61) | 38 (9; 58) | 0 (−19; 21) | ||||
| CPAQ, 0–120 | 63.6 (16.1) | 69.6 (15.2) | 5.7 (13.1) |
| 62.4 (17.1) | 63.4 (19.1) | 0.1 (11.8) | 0.79 |
|
| 63 (19; 106) | 69 (34; 98) | 6 (−27; 46) | 61 (15; 107) | 60 (30; 113) | 2 (−38; 23) | ||||
| FABQphysical, 0–24 | 9.7 (6.1) | 8.9 (6.1) | −0.8 (7.0) | 0.36 | 11.2 (6.1) | 10.3 (6.3) | −1.3 (5.6) | 0.24 | 0.92 |
| 9 (0; 24) | 8 (0; 22) | −1 (−19;19) | 11 (0; 24) | 9 (0; 24) | 0 (−18;10) | ||||
| FABQwork, 0–42 | 17.2 (12.7) | 17.8 (13.1) | 0.4 (8.9) | 0.83 | 15.9 (12.1) | 16.67 (12.5) | 1.2 (8.1) | 0.54 | 0.79 |
| 16 (0; 42) | 16 (0; 42) | 0 (−27; 29) | 12 (0; 42) | 14 (0; 42) | 0 (−19; 30) | ||||
Missing values at baseline: Resistance exercise group, SF36 PCS and SF36 MCS, n = 1; FABQwork, n = 6, FABQphysical, n = 1; Relaxation therapy group, CPAQ, n = 1; FABQwork, n = 8. Missing post-test values: Resistance exercise group, SF36 MCS and PCS, n = 3; FABQwork, n = 7; FABQphysical, n = 2; Relaxation therapy group, FIQtotal, n = 1; SF36 PCS and MCS, n = 2; FABQwork, n = 9. Significant p values are shown in bold text. 6MWT six-minute walk test, FIQ fibromyalgia impact questionnaire, VAS visual analog scale, SF36 short-form 36, PDI pain disability index, CPAQ chronic pain acceptance questionnaire, FABQ fear avoidance beliefs questionnaire
Between-group analysis and within-group analysis of outcomes assessed at follow up after 13–18 months
| Measures | Resistance exercise (experimental) | Relaxation therapy (control) | Between group analysis for change | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline | 13–18 month follow up | Follow up- baseline | Within-group analysis | Baseline | 13–18 month follow up | Follow up-baseline | Within-group analysis | ||
| (n = 67) | (n = 48) | (n = 48) | (n = 63) | (n = 43) | (n = 43) | ||||
| Mean (SD) | Mean (SD) | Δ (SD) |
| Mean (SD) | Mean (SD) | Δ (SD) |
|
| |
| Median (min; max) | Median (min; max) | Δ (min; max) | Median (min; max) | Median (min; max) | Δ (min; max) | ||||
| Secondary outcomes | |||||||||
| FIQ total, 0–100 | 60.5 (14.4) | 57.1 (19.4) | −1.8 (17.0) | 0.71 | 61.1 (17.3) | 55.4 (17.0) | −3.4 (12.3) | 0.065 | 0.35 |
| 59 (31; 95) | 59 (17; 92) | 1 (−45; 35) | 61 (17; 88) | 55 (15; 90) | −3 (−28; 36) | ||||
| Current pain intensity, VAS | 49.3 (23.9) | 49.2 (20.8) | 0.7 (23.4) | 0.87 | 52.4 (18.3) | 52.1 (19.5) | −2.9 (19.6) | 0.45 | 0.52 |
| 50 (5; 100) | 47 (9; 84) | 3 (−73; 58) | 51 (10; 88) | 53 (5; 83) | −2 (−62; 46) | ||||
| SF36 PCS, 0–100 | 31.2 (7.9) | 32.2 (8.0) | 0.8 (7.1) | 0.39 | 29.9 (8.1) | 32.0 (9.4) | 1.9 (7.3) | 0.16 | 0.62 |
| 31 (12; 50) | 30 (17; 54) | 1 (−14; 14) | 30 (10; 49) | 32 (17; 52) | 1 (−13; 19) | ||||
| SF36 MCS, 0–100 | 37.7 (12.2) | 39.2 (13.9) | −0.4 (13.5) | 0.78 | 39.6 (12.1) | 40.0 (11.9) | −0.4 (12.2) | 0.66 | 0.89 |
| 37 (10; 61) | 39 (10; 59) | 0 (−28; 29) | 42 (16; 59) | 43 (19; 60) | −2 (−23; 28) | ||||
| PDI, 0–70 | 35.3 (12.2) | 33.0 (11.6) | −2.6 (9.7) | 0.094 | 35.0 (12.5) | 33.7 (10.9) | −0.3 (10.1) | 0.58 | 0.42 |
| 36 (8; 69) | 34 (7; 62) | −3 (−28; 17) | 34 (7; 61) | 35 (8; 54) | −1 (−21; 25) | ||||
| CPAQ total, 0–120 | 63.6 (16.1) | 68.0 (15.4) | 3.6 (11.3) |
| 62.4 (17.1) | 66.6 (17.1) | 2.3 (14.0) | 0.21 | 0.76 |
| 63 (19; 106) | 70 (33; 100) | 3 (−21; 32) | 61 (15; 107) | 63 (24; 101) | 1 (−35; 28) | ||||
| FABQphysical, 0–24 | 9.7 (6.1) | 10.1 (5.2) | −0.1 (5.5) | 0.57 | 11.2 (6.1) | 9.7 (6.3) | −1.6 (4.5) | 0.051 | 0.38 |
| 9 (0; 24) | 10 (2; 21) | 0 (−10; 17) | 11 (0; 24) | 10 (0; 24) | −1 (−14; 5) | ||||
| FABQwork, 0–42 | 17.2 (12.7) | 15.5 (11.5) | −1.8 (9.7) | 0.20 | 15.9 (12.1) | 14.7 (12.4) | −1.0 (11.2) | 0.66 | 0.59 |
| 16 (0; 42) | 14 (0; 41) | −1 (−30; 32) | 12 (0; 42) | 13 (0; 42) | 0 (−41; 30) | ||||
Missing values at baseline: Resistance exercise group, SF36 PCS and SF36 MCS, n = 1; FABQwork, n = 6; FABQphysical, n = 1. Relaxation therapy group, CPAQ, n = 1; FABQwork, n = 8. Missing values at 13–18 month follow up, Resistance exercise group, current pain intensity, n = 2; FABQwork, n = 5; SF36 PCS and SF36 MCS, n = 1. Relaxation therapy group, FABQwork, n = 7; FABQphysical, n = 1; SF36 PCS and SF36 MCS, n = 1. Significant p values are shown in bold text. FIQ fibromyalgia impact questionnaire, VAS visual analog scale, SF36 short-form 36, PDI pain disability index, CPAQ chronic pain acceptance questionnaire, FABQ fear avoidance beliefs questionnaire